HC Wainwright Has Bearish Estimate for Altimmune Q2 Earnings

Altimmune, Inc. (NASDAQ:ALT) – Investment analysts at HC Wainwright lowered their Q2 2025 EPS estimates for Altimmune in a research note issued on Monday, March 3rd. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($0.34) per share for the quarter, down from their previous forecast of ($0.33). HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Altimmune’s current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for Altimmune’s FY2025 earnings at ($1.34) EPS, Q1 2026 earnings at ($0.38) EPS, Q2 2026 earnings at ($0.34) EPS, Q3 2026 earnings at ($0.34) EPS, Q4 2026 earnings at ($0.34) EPS, FY2026 earnings at ($1.40) EPS, FY2027 earnings at ($1.40) EPS and FY2028 earnings at ($0.14) EPS.

Other equities research analysts have also recently issued reports about the company. UBS Group started coverage on Altimmune in a report on Tuesday, November 12th. They set a “buy” rating and a $26.00 price target for the company. Stifel Nicolaus assumed coverage on Altimmune in a report on Wednesday, January 8th. They set a “buy” rating and a $18.00 price objective on the stock. Finally, William Blair began coverage on Altimmune in a report on Friday, February 28th. They issued a “market perform” rating on the stock. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Altimmune has an average rating of “Moderate Buy” and an average price target of $20.83.

Altimmune Trading Down 2.3 %

Shares of Altimmune stock opened at $5.59 on Thursday. Altimmune has a 1-year low of $5.28 and a 1-year high of $11.50. The firm’s 50-day moving average price is $6.70 and its two-hundred day moving average price is $7.17. The stock has a market capitalization of $430.51 million, a price-to-earnings ratio of -3.61 and a beta of 0.87.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.01. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.00 million.

Institutional Investors Weigh In On Altimmune

Several hedge funds have recently bought and sold shares of ALT. Larson Financial Group LLC acquired a new position in Altimmune in the 3rd quarter valued at about $31,000. SBI Securities Co. Ltd. bought a new stake in shares of Altimmune during the fourth quarter worth approximately $45,000. Virtus ETF Advisers LLC acquired a new position in shares of Altimmune in the fourth quarter valued at approximately $60,000. Cullen Frost Bankers Inc. bought a new position in shares of Altimmune during the fourth quarter worth approximately $72,000. Finally, 180 Wealth Advisors LLC acquired a new stake in Altimmune during the 4th quarter worth approximately $78,000. 78.05% of the stock is currently owned by institutional investors and hedge funds.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.